ODAC says prostate cancer patients who lack proven BRCA mutation shouldn’t get PARP inhibitor

The FDA Oncologic Drugs Advisory Committee agreed with the agency’s forcefully stated view that Lynparza (olaparib), a PARP inhibitor, should be given only to metastatic castration-resistant prostate cancer patients whose tumors have a BRCA mutation.